drugset / Trial / NCT00698243
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in patients with advanced solid tumors or lymphoma, namely, intermittent, weekly, and continuous.
Timeline
- Start
- 2008-06
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OSI-027 | Small molecule | — | Oral |
Indications
No indication recorded.